Your session is about to expire
← Back to Search
Diagnostic Test
A Proof-of-Concept Study Evaluating LINFU™
N/A
Waitlist Available
Led By Scott Corbett, MD, FASGE
Research Sponsored by Adenocyte, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 months
Awards & highlights
No Placebo-Only Group
Summary
This trial uses the LINFU™ Technique, which employs ultrasound and a special dye to collect pancreatic fluid. It targets people at high risk for pancreatic cancer. The method involves stimulating the pancreas to release fluid, which is then collected and analyzed.
Eligible Conditions
- Pancreatic Adenocarcinoma
- Dysplasia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 4 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Does LINFU™ yield an adequate number of cells that can be used to help diagnose pancreatic precancers and cancers?
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: The LINFU™ testExperimental Treatment1 Intervention
LINFU™ to increase sensitivity of pancreatic juice cytology LINFU™ consists of analysis of pancreatic fluid collected with the help of low intensity non-focused ultrasound excitation of the pancreas. Lumason, will be used to create bubbles and possibly increase the number of pancreatic cell we collect for the study. Secretin is also used to increase the number of pancreatic cell excretion to maximize the number of cells collected.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LINFU™
2021
N/A
~20
Find a Location
Who is running the clinical trial?
Adenocyte, LLCLead Sponsor
5 Previous Clinical Trials
3,500 Total Patients Enrolled
Scott Corbett, MD, FASGEPrincipal InvestigatorSuncoast Endoscopy of Sarasota (a division of Florida Digestive Health Specialists)